{"component": "definition", "props": {"groups": [{"size": 41, "samples": [{"hash": "2Y2ghIveISr", "uri": "/contracts/2Y2ghIveISr#milestone-event", "label": "License Agreement (Jounce Therapeutics, Inc.)", "score": 30.8480491638, "published": true}, {"hash": "32pDZuR3QbP", "uri": "/contracts/32pDZuR3QbP#milestone-event", "label": "License Agreement (Agenus Inc)", "score": 30.2073917389, "published": true}, {"hash": "aD9LGmIj5Hb", "uri": "/contracts/aD9LGmIj5Hb#milestone-event", "label": "Master Development and License Agreement (Concert Pharmaceuticals, Inc.)", "score": 25.0903491974, "published": true}], "snippet": "has the meaning set forth in Section 7.2.1.", "snippet_links": [{"key": "section-721", "type": "clause", "offset": [29, 42]}], "hash": "4e86c95c0cb14b00060d44fcf87bca43", "id": 1}, {"size": 37, "samples": [{"hash": "3dqouoc4u1f", "uri": "/contracts/3dqouoc4u1f#milestone-event", "label": "License Agreement (Arcturus Therapeutics Ltd.)", "score": 29.5201911926, "published": true}, {"hash": "irSMMh7qu3h", "uri": "/contracts/irSMMh7qu3h#milestone-event", "label": "License Agreement (Arcturus Therapeutics Ltd.)", "score": 29.3641338348, "published": true}, {"hash": "nL0iKK19jo", "uri": "/contracts/nL0iKK19jo#milestone-event", "label": "License Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 24.8275146484, "published": true}], "snippet": "shall have the meaning set forth in Section 4.2.", "snippet_links": [{"key": "section-42", "type": "clause", "offset": [36, 47]}], "hash": "e50f64b4ef8eef0836dd828e11957493", "id": 2}, {"size": 37, "samples": [{"hash": "25tl54bJL63", "uri": "/contracts/25tl54bJL63#milestone-event", "label": "Master Collaboration and License Agreement", "score": 32.8346099854, "published": true}, {"hash": "5RZPiYInoI7", "uri": "/contracts/5RZPiYInoI7#milestone-event", "label": "Master Collaboration and License Agreement (Moderna, Inc.)", "score": 29.8542098999, "published": true}, {"hash": "8SXfpMngZh8", "uri": "/contracts/8SXfpMngZh8#milestone-event", "label": "Master Collaboration and License Agreement (Moderna, Inc.)", "score": 29.8295688629, "published": true}], "snippet": "has the meaning set forth in Section 8.4.", "snippet_links": [{"key": "section-84", "type": "clause", "offset": [29, 40]}], "hash": "9fdba1471a75373f7ea2c779c67c0460", "id": 3}, {"size": 33, "samples": [{"hash": "3QyANbAdDNa", "uri": "/contracts/3QyANbAdDNa#milestone-event", "label": "Asset Purchase Agreement (Aralez Pharmaceuticals Inc.)", "score": 27.9267616272, "published": true}, {"hash": "4ge171x3wAn", "uri": "/contracts/4ge171x3wAn#milestone-event", "label": "Asset Purchase Agreement (Aralez Pharmaceuticals Inc.)", "score": 27.6858310699, "published": true}, {"hash": "eCFSp02HdyB", "uri": "/contracts/eCFSp02HdyB#milestone-event", "label": "Asset Purchase Agreement (Pernix Therapeutics Holdings, Inc.)", "score": 26.6290206909, "published": true}], "snippet": "has the meaning set forth in Section 2.3.2(a).", "snippet_links": [], "hash": "6a29a57a118396381c5ced06f711616f", "id": 4}, {"size": 22, "samples": [{"hash": "dOZzLDIUhua", "uri": "/contracts/dOZzLDIUhua#milestone-event", "label": "Collaboration Agreement (Adagio Therapeutics, Inc.)", "score": 32.5373039246, "published": true}, {"hash": "2ZNIKLGOxtW", "uri": "/contracts/2ZNIKLGOxtW#milestone-event", "label": "Collaboration Agreement (iTeos Therapeutics, Inc.)", "score": 32.3620796204, "published": true}, {"hash": "cEHdIquPD46", "uri": "/contracts/cEHdIquPD46#milestone-event", "label": "Collaboration Agreement (Cullinan Oncology, LLC)", "score": 31.96235466, "published": true}], "snippet": "has the meaning set forth in Section 4.4(a) (Milestone Events).", "snippet_links": [{"key": "milestone-events", "type": "clause", "offset": [45, 61]}], "hash": "fd43738bd745d9ca78e3c1ebac52c160", "id": 5}, {"size": 22, "samples": [{"hash": "9xFachPRQ96", "uri": "/contracts/9xFachPRQ96#milestone-event", "label": "License and Collaboration Agreement (Constellation Pharmaceuticals Inc)", "score": 29.5174541473, "published": true}, {"hash": "44cYuA4rg53", "uri": "/contracts/44cYuA4rg53#milestone-event", "label": "License and Collaboration Agreement (Constellation Pharmaceuticals Inc)", "score": 29.470911026, "published": true}, {"hash": "5avN2sEBdKN", "uri": "/contracts/5avN2sEBdKN#milestone-event", "label": "License and Collaboration Agreement (Constellation Pharmaceuticals Inc)", "score": 29.3175907135, "published": true}], "snippet": "means a Research and Development Milestone Event or a Commercialization Milestone Event.", "snippet_links": [{"key": "development-milestone-event", "type": "definition", "offset": [21, 48]}, {"key": "commercialization-milestone-event", "type": "definition", "offset": [54, 87]}], "hash": "c03d169c87933d12b370bd91f623affc", "id": 6}, {"size": 21, "samples": [{"hash": "5pU174hVxJB", "uri": "https://www.natrax.in/wp-content/uploads/2024/08/tender-doc-1.pdf", "label": "Notice", "score": 23.3765583038, "published": false}, {"hash": "3zB0ACucIC5", "uri": "https://www.natrax.in/wp-content/uploads/2024/08/tender-documents.pdf", "label": "Notice", "score": 23.2518138885, "published": false}, {"hash": "e466WbFo3fU", "uri": "https://www.natrax.in/wp-content/uploads/2024/01/63R.pdf", "label": "Notice", "score": 16.0855579376, "published": false}], "snippet": "means the completion of a specific activity and shall include the extent of progress of works (if any) as specified in the Special Conditions of Contract, to be achieved, which reflects progress in the design and Execution of the Works or the occurrence of an event in each case as identified as such in the Payment Schedule.", "snippet_links": [{"key": "completion-of-a", "type": "clause", "offset": [10, 25]}, {"key": "specific-activity", "type": "definition", "offset": [26, 43]}, {"key": "progress-of-works", "type": "clause", "offset": [76, 93]}, {"key": "as-specified", "type": "clause", "offset": [103, 115]}, {"key": "special-conditions-of-contract", "type": "clause", "offset": [123, 153]}, {"key": "the-design", "type": "clause", "offset": [198, 208]}, {"key": "execution-of-the-works", "type": "clause", "offset": [213, 235]}, {"key": "occurrence-of-an-event", "type": "clause", "offset": [243, 265]}, {"key": "each-case", "type": "definition", "offset": [269, 278]}, {"key": "payment-schedule", "type": "definition", "offset": [308, 324]}], "hash": "b411eb0f69bc36d721023390d064c5ca", "id": 7}, {"size": 17, "samples": [{"hash": "jjfB0wnNz08", "uri": "/contracts/jjfB0wnNz08#milestone-event", "label": "License Agreement (XTL Biopharmaceuticals LTD)", "score": 21.0, "published": true}, {"hash": "hiS4yw8iEfg", "uri": "/contracts/hiS4yw8iEfg#milestone-event", "label": "License Agreement (Cubist Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "f0wtuiy2jBX", "uri": "/contracts/f0wtuiy2jBX#milestone-event", "label": "License Agreement (Cubist Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet": "shall have the meaning set forth in Section 9.2(a).", "snippet_links": [], "hash": "b741682c340a3e05524c9aa8bf7c6055", "id": 8}, {"size": 17, "samples": [{"hash": "62UigPmAr3u", "uri": "/contracts/62UigPmAr3u#milestone-event", "label": "License Agreement (Alto Neuroscience, Inc.)", "score": 34.9876785278, "published": true}, {"hash": "bBYqzLN0Hib", "uri": "/contracts/bBYqzLN0Hib#milestone-event", "label": "License Agreement (First Wave BioPharma, Inc.)", "score": 34.7713890076, "published": true}, {"hash": "bOjtSdf806j", "uri": "https://www.sec.gov/Archives/edgar/data/1385508/000138550818000119/opiant_sanofixave1625licen.htm", "label": "License Agreement (Opiant Pharmaceuticals, Inc.)", "score": 20.988363266, "published": false}], "snippet": "means each of the events identified as a milestone event in Section 6.2.1 or Section 6.2.2.", "snippet_links": [{"key": "the-events", "type": "clause", "offset": [14, 24]}, {"key": "section-621", "type": "clause", "offset": [60, 73]}, {"key": "section-622", "type": "clause", "offset": [77, 90]}], "hash": "42ae9bb76ebd002fa2a79baf2ac92e37", "id": 9}, {"size": 16, "samples": [{"hash": "lk46uYToBKr", "uri": "/contracts/lk46uYToBKr#milestone-event", "label": "License Agreement (BioNTech SE)", "score": 31.5516777039, "published": true}, {"hash": "gEfF0q72SP2", "uri": "/contracts/gEfF0q72SP2#milestone-event", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "8lRrZYFYGZv", "uri": "/contracts/8lRrZYFYGZv#milestone-event", "label": "License Agreement (Neon Therapeutics, Inc.)", "score": 29.4106769562, "published": true}], "snippet": "means any milestone event indicated in Section 4.3.1 or Section 4.3.2.", "snippet_links": [{"key": "section-431", "type": "clause", "offset": [39, 52]}], "hash": "ef425da19282507dc08897f0dc4a2ef2", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYbWlsZXN0b25lLWV2ZW50IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 778, "snippet": "has the meaning set forth in Section 7.2.1.", "title": "Milestone Event", "id": "milestone-event", "examples": ["Each Manufacturing Milestone Payment shall be payable one-time, upon the first achievement of such Manufacturing <strong>Milestone Event</strong>.", "If the applicable Development and Regulatory <strong>Milestone Event</strong> is achieved during the U.S. P&amp;L Share Term, then Company will pay Vir Bio the following corresponding Development and Regulatory Milestone Payment for such Development and Regulatory <strong>Milestone Event</strong>.", "If the applicable Development and Regulatory <strong>Milestone Event</strong> is achieved after the end of the U.S. P&amp;L Share Term and Vir Bio has not achieved the Limited Funding Threshold at such time, then Company will pay Vir Bio the following corresponding Development and Regulatory Milestone Payment (\u201cOpt-Out Development and Regulatory Milestone Payment\u201d) for such Development and Regulatory <strong>Milestone Event</strong>.", "For the avoidance of doubt, if a Development and Regulatory <strong>Milestone Event</strong> was achieved or deemed to be achieved during the U.S. P&amp;L Share Term, then in no event shall the same underlying Development and Regulatory <strong>Milestone Event</strong> be achieved or deemed to be achieved after the end of the U.S. P&amp;L Share Term, nor shall the corresponding Opt-Out Development and Regulatory Milestone Payment or Limited Funding Development and Regulatory Milestone Payment be paid.", "Company shall notify Vir Bio of achievement by Company, its Affiliates, or Sublicensees of the manufacturing <strong>milestone events</strong> described in the table below (each a \u201cManufacturing <strong>Milestone Event</strong>\u201d) [***] after the corresponding Manufacturing <strong>Milestone Event</strong> is achieved.", "Company shall notify Vir Bio of the first achievement by Company, its Affiliates or Sublicensees of each of the development and regulatory <strong>milestone events</strong> described in the tables below (as applicable) (each a \u201cDevelopment and Regulatory <strong>Milestone Event</strong>\u201d) [***] after the corresponding Development and Regulatory <strong>Milestone Event</strong> is achieved.", "If the applicable Sales <strong>Milestone Event</strong> is achieved after the end of the U.S. P&amp;L Share Term and Vir Bio has not achieved the Limited Funding Threshold at such time, then Company will pay Vir Bio the following Sales Milestone Payment (\u201cOpt-Out Sales Milestone Payment\u201d) for such Sales <strong>Milestone Event</strong>.", "Upon such achievement of a Sales <strong>Milestone Event</strong>, Company shall pay Vir Bio the sales milestone payment described in the applicable table below for the applicable Sales <strong>Milestone Event</strong> (each a \u201cSales Milestone Payment\u201d) [***] after receipt of an invoice therefor from Vir Bio, [***].", "Company shall notify Vir Bio of the first achievement of each sales <strong>milestone event</strong> described in the tables below (as applicable) (each a \u201cSales <strong>Milestone Event</strong>\u201d) [***] after the end of the Calendar Quarter in the Calendar Year in which such Sales <strong>Milestone Event</strong> is first achieved.", "Notwithstanding any other provision herein, each Sales Milestone Payment shall be payable one-time, upon the first achievement of such Sales <strong>Milestone Event</strong> (for clarity, regardless of the number of Licensed Products to achieve a Sales <strong>Milestone Event</strong>)."], "related": [["development-milestone-event", "Development Milestone Event", "Development <strong>Milestone Event</strong>"], ["sales-milestone-event", "Sales Milestone Event", "Sales <strong>Milestone Event</strong>"], ["milestone-events", "Milestone Events", "<strong>Milestone Events</strong>"], ["milestone", "Milestone", "Milestone"], ["milestone-2", "Milestone 2", "Milestone 2"]], "related_snippets": [], "updated": "2026-05-28T05:54:56+00:00"}, "json": true, "cursor": ""}}